Glatiramer acetate in treatment-naïve and prior interferon-β-1b- treated multiple sclerosis patients

Acta Neurologica Scandinavica

Volumn 113, Issue 6, 2006, Pages 378-386

  Zwibel, H L ^a,b  

^a Doctors Hospital/Health South   (United States)

^b NONE   (United States)

Author keywords

Betaseron; Copaxone; EDSS; Glatiramer acetate; Interferon 1b; Relapse; Relapsing remitting multiple sclerosis

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; GLATIRAMER; INTERFERON BETA SERINE; LIVER ENZYME;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACCIDENTAL INJURY; ADULT; ARTICLE; ASTHMA; BREAST CANCER; CANCER; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; ILEUS; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MOBILIZATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PSYCHOSIS; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SINGLE DRUG DOSE; SYNCOPE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE DISTRIBUTION; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 33745923816     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00627.x     Document Type: Article

References (18)

1. JOHNSON KP, BROOKS BR, COHEN JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology 1995;45:1268-76.
2. JOHNSON KP, BROOKS BR, COHEN JA et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-8.
3. COMI G, FILIPPI M, WOLINSKY JS et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7.
4. JACOBS LD, COOKFAIR DI, RUDICK RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
5. IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
6. Prisms Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
7. JEFFERY DR. Early intervention with immunomodulatory agents in the treatment of multiple sclerosis. J Neurol Sci 2002;197:1-8.
8. YONG VW. Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology 2002;59:802-8.
9. MILO R, PANITCH H. Glatiramer acetate or interferon-β for multiple sclerosis. A guide to drug choice. CNS Drugs 1999;11:289-306.
10. Teva Neuroscience Inc. Copaxone® (glatiramer acetate injection) prescribing information. Kansas City, MO: Teva Neuroscience Inc., 2002.
11. WAUBANT E, VUKUSIC S, GIGNOUX L et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-9.
12. CAON C, CHING W, DIN M, ZVARTAU-HIND M, LISAK R, KHAN O. Extended follow-up and clinical course after change of immunomodulatory therapy in relapsing-remitting MS. Proceedings of the 13th Annual Meeting of the European Neurological Society, Istanbul, Turkey, 2003.
13. POSER CM, PAY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
14. KURTZKE JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
15. JOHNSON KP, BROOKS BR, FORD CC et al. Glatiramer acetate (Copaxone®): comparison of continuous versus delayed therapy in a six year organized multiple sclerosis trial. Mult Scler 2003;9:585-91.
16. JOHNSON KP, FORD CC, LISAK RP et al. Glatiramer acetate (Copaxone®): neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005;111:42-7.
17. FORD C, JOHNSON K, BROOKS B et al . Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over 10 years. Proceedings of the 19th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Milan, Italy, 2003;485.
18. CONFAVREUX C, VUKUSIC S, MOREAU T, ADELEINE P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.